Pancreatic Cancer Research

ResearcherGuangdong General HospitalNo recent work listed

Zhixiang Jian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7258-352X; OpenAlex author ID A5068016013. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers

Papers 9

  1. Anterior gradient 2 is a novel pro-tumor factor in pancreatic cancer under NF-κB subunit RelA trans-regulation that can be suppressed by eugenic acid. Last author DOI 10.1016/j.biopha.2020.110830↗
  2. Prognostic value of lymphocyte to monocyte ratio in pancreatic cancer: a systematic review and meta-analysis including 3338 patients. Last author DOI 10.1186/s12957-020-01962-0↗
  3. The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.1186/s13014-020-01511-9↗
  4. Prognostic value of tumor-associated macrophages in pancreatic cancer: a meta-analysis. Last author DOI 10.2147/cmar.s196951↗
  5. Genome-Wide Profiling of Prognostic Alternative Splicing Pattern in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2019.00773↗
  6. Revision of Surgical Margin under Frozen Section to Achieve R0 Status on Survival in Patients with Pancreatic Cancer. Last author DOI 10.1007/s11605-018-3806-x↗
  7. Pretreatment platelet count as a prognostic factor in patients with pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.2147/ott.s147715↗
  8. Association and Intragenic Single-Nucleotide Polymorphism Interactions of the XRCC1 Polymorphisms for Pancreatic Cancer Susceptibility. First author DOI 10.1097/mpa.0000000000000482↗
  9. [Expression of miR-216a in pancreatic cancer and its clinical significance]. First author PMID 23174591↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baohua Hou · 6 shared papers, 2012–2020 · strength 0.51
  2. Haosheng Jin · 3 shared papers, 2019–2020 · strength 0.31
  3. Min Yu · 3 shared papers, 2018–2019 · strength 0.28
  4. Shiye Ruan · 2 shared papers, 2019–2020 · strength 0.21
  5. Sheng Chen · 1 shared paper, 2018 · strength 0.14
  6. Shuwen Lin · 1 shared paper, 2020 · strength 0.13
  7. Ning Shi · 1 shared paper, 2020 · strength 0.12
  8. Liang Jin · 1 shared paper, 2020 · strength 0.12
  9. Yiping Zou · 1 shared paper, 2020 · strength 0.12
  10. Jinrui Ou · 2 shared papers, 2012–2016 · strength 0.11
  11. Jiangzhi Chen · 1 shared paper, 2020 · strength 0.11
  12. Ge Li · 1 shared paper, 2020 · strength 0.11
  13. Can Yang · 1 shared paper, 2020 · strength 0.11
  14. Yifeng Tian · 1 shared paper, 2020 · strength 0.11
  15. Huatian Luo · 1 shared paper, 2020 · strength 0.11
  16. Yaodong Wang · 1 shared paper, 2020 · strength 0.11
  17. Long Huang · 1 shared paper, 2020 · strength 0.11
  18. Shi Chen · 1 shared paper, 2020 · strength 0.11
  19. Chuanzhao Zhang · 1 shared paper, 2018 · strength 0.09
  20. Zi Yin · 1 shared paper, 2018 · strength 0.09
  21. Yu Zhou · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.